HighTower Advisors
FLNA

HighTower Advisors’s Filana Therapeutics FLNA Stock Holding History

HighTower Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20
Closed -$45K – 3488
2022
Q3 		$45K Buy
+20
New +$540 ﹤0.01% 2895
2021
Q2 		– Sell
-20
Closed -$22K – 3357
2021
Q1 		$22K Buy
+20
New +$787 ﹤0.01% 2895

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HighTower Advisors's FLNA Position: Q4 2022 in Review

HighTower Advisors sold out of Filana Therapeutics (FLNA) in Q4 2022, closing a stake of 6,320 shares — an estimated $264K sold.

HighTower Advisors first reported a position in FLNA in Q1 2021 and held it in 6 quarters. The position peaked at $1.85M in Q3 2021. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2022.

  • HighTower Advisors reported no remaining Filana Therapeutics position as of Q4 2022 after selling out during the quarter.
  • HighTower Advisors sold 6,320 Filana Therapeutics shares in Q4 2022, an estimated $264K.
  • HighTower Advisors first reported a position in Filana Therapeutics in Q1 2021 and held it in 6 quarters.
  • HighTower Advisors's Filana Therapeutics position peaked at $1.85M in Q3 2021.
  • 153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2022.

Based on HighTower Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.